Urt.Wa

URT.WA's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. The company holds $1.46 million in cash and equivalents, while its total liabilities amount to $5.51 million. The current ratio of 10.33 suggests strong short-term liquidity, with current assets significantly outpacing current liabilities. However, the company's operating cash flow is negative at -$5.47 million, and free cash flow is -$11.48 million, indicating ongoing cash burn.

Profitability metrics for URT.WA are negative, with a return on equity of -15.06% and a return on assets of -12.26%. These figures are below the industry median for biotechnology firms, which typically exhibit higher returns during growth phases. The company's net loss of $3.63 million and operating loss of $4.17 million further underscore its unprofitable operations. Gross profit is also negative at -$298,000, suggesting that the company is not yet achieving economies of scale or pricing power in its product offerings.

The company's revenue is reported as $0, indicating that it is not currently generating revenue from operations. This suggests that URT.WA is in an early-stage development phase, likely focused on research and development of diagnostic products. There is no disclosed geographic revenue concentration, and the company does not report any operating segments, which may indicate a single-product or single-service focus.

The company's growth trajectory is not yet defined, as there is no historical revenue data to establish a growth pattern. The absence of revenue and the negative operating cash flow suggest that URT.WA is in a pre-revenue or early-revenue phase. The company's capital expenditures of -$8.96 million indicate significant investment in infrastructure or R&D, which is typical for early-stage biotechnology firms. However, without a clear path to revenue generation, the company's long-term growth potential remains uncertain.

Risk factors for URT.WA include its lack of revenue and ongoing cash burn, which could lead to liquidity constraints if the company is unable to secure additional financing. The company's dilution risk is currently low, as there are no immediate filing-based flags for dilution. However, the company's reliance on external financing to fund operations increases the potential for future dilution events. The company's low debt-to-equity ratio suggests that it is not currently using debt as a primary source of capital, but this could change if equity financing becomes too costly.

Recent events for URT.WA include the latest financial filing, which shows continued losses and no revenue generation. There are no disclosed recent earnings calls or transcripts, and the company has not issued any material updates in the public domain. The absence of recent events suggests that the company is in a quiet phase of development, with no major announcements or strategic shifts reported.